COGT
COGT clinical trials: Cogent Biosciences, Inc.
Every trial on ClinicalTrials.gov where Cogent Biosciences, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 15
- Trials linked
- 14
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
COGT on the catalyst calendar · COGT registry changes
- Primary completion Sep 30, 2025ActualPhase 3NCT05208047(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal TumorsCogent Biosciences, Inc. · Advanced Gastrointestinal Stromal TumorsRecruitingCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2029Sponsor estimatePhase 1NCT07383506A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsCogent Biosciences, Inc. · PIK3CA MutationsRecruitingCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2025ActualPhase 2NCT05186753(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisCogent Biosciences, Inc. · SSMActive, not recruitingCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2025ActualPhase 2NCT04996875(Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisCogent Biosciences, Inc. · Advanced Systemic Mastocytosis (AdvSM)RecruitingCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 1NCT07361562A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsCogent Biosciences, Inc. · Advanced Solid Tumor, AdultRecruitingCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06948955Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal TumorsCogent Biosciences, Inc. · Gastrointestinal Neoplasms, Gastrointestinal Stromal TumorsAvailableCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06915766Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic MastocytosisCogent Biosciences, Inc. · Systemic Mastocytoses, IndolentAvailableCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1/Phase 2NCT06777316A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid TumorsCogent Biosciences, Inc. · Intrahepatic Cholangiocarcinoma (Icc)Active, not recruitingCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2020ActualPhase 1/Phase 2NCT02401815CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With...Cogent Biosciences, Inc. · Gastrointestinal Stromal TumorsCompletedCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 21, 2020ActualPhase 1NCT03189836Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell LymphomaCogent Biosciences, Inc. · LymphomaTerminatedCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2020ActualNo phase registeredNCT02840110Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell ProductCogent Biosciences, Inc. · B Cell LymphomasTerminatedCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 12, 2020ActualPhase 1NCT03680560Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor CancersCogent Biosciences, Inc. · Solid TumorTerminatedCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2019ActualPhase 1NCT03266692Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple MyelomaCogent Biosciences, Inc. · Multiple MyelomaTerminatedCOGTLeadPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 12, 2020ActualPhase 1NCT02776813Study of ACTR087 in Subjects With Relapsed or Refractory B-cell LymphomaCogent Biosciences, Inc. · LymphomaCompletedCOGTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2026Sponsor estimatePhase 2NCT06208748SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GISTSarcoma Alliance for Research through Collaboration · Gastrointestinal Stromal TumorsActive, not recruitingCOGTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner